{"id":"lumiracoxib","rwe":[{"pmid":"41002919","year":"2025","title":"Lipid Raft Membrane Interactivity Correlating with Cyclooxygenase-2 Selectivity of Non-Steroidal Anti-Inflammatory Drugs.","finding":"","journal":"Membranes","studyType":"Clinical Study"},{"pmid":"40859326","year":"2025","title":"The STUB1-TPIT axis regulates the secretion of adrenocorticotrophic hormone in cushing disease.","finding":"","journal":"Journal of translational medicine","studyType":"Clinical Study"},{"pmid":"39770440","year":"2024","title":"Cyclodextrin-Nanosponge-Loaded Cyclo-Oxygenase-2 Inhibitor-Based Topical Gel for Treatment of Psoriatic Arthritis: Formulation Design, Development, and In vitro Evaluations.","finding":"","journal":"Pharmaceuticals (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"39510245","year":"2025","title":"The role of the cyclooxygenase-2 pathway in tissue ischemia and revascularization following skeletal muscle injury induced by bothropic snake venom.","finding":"","journal":"Microvascular research","studyType":"Clinical Study"},{"pmid":"39114538","year":"2024","title":"Renal effects of selective cyclooxygenase-2 inhibitor anti-inflammatory drugs: A systematic review and meta-analysis.","finding":"","journal":"Exploratory research in clinical and social pharmacy","studyType":"Clinical Study"}],"tags":[{"label":"lumiracoxib","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Prostaglandin G/H synthase 1","category":"target"},{"label":"PTGS1","category":"gene"},{"label":"PTGS2","category":"gene"},{"label":"M01AH06","category":"atc"},{"label":"Active","category":"status"},{"label":"Osteoarthritis","category":"indication"},{"label":"Novartis Pharmaceuticals UK Limited","category":"company"},{"label":"Analgesics","category":"pharmacology"},{"label":"Analgesics, Non-Narcotic","category":"pharmacology"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Anti-Inflammatory Agents, Non-Steroidal","category":"pharmacology"},{"label":"Antirheumatic Agents","category":"pharmacology"},{"label":"Cyclooxygenase 2 Inhibitors","category":"pharmacology"},{"label":"Cyclooxygenase Inhibitors","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Novartis Pharmaceuticals UK Limited","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=LUMIRACOXIB","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:22:00.100972+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T01:22:15.453664+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:22:06.179632+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LUMIRACOXIB","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:22:06.545610+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Cyclooxygenase-2 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:22:07.600996+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL404108/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:22:07.248974+00:00"}},"allNames":"joicela","offLabel":[],"synonyms":["joicela","lumiracoxib","prexige"],"timeline":[{"date":"2003-09-12","type":"positive","source":"DrugCentral","milestone":"UK Medicines and Healthcare Products Regulatory Agency (MHRA) approval (Novartis Pharmaceuticals UK Limited)"}],"aiSummary":"Lumiracoxib (Joicela), marketed by Novartis Pharmaceuticals UK Limited, is a selective inhibitor of Prostaglandin G/H synthase 1, primarily indicated for osteoarthritis. Its key strength lies in its selective mechanism, which may offer a favorable safety profile compared to non-selective NSAIDs. The primary risk is the upcoming key composition patent expiry in 2028, which could lead to increased competition from generics.","approvals":[{"date":"2003-09-12","orphan":false,"company":"Novartis Pharmaceuticals UK Limited","regulator":"UK Medicines and Healthcare Products Regulatory Agency (MHRA)"}],"brandName":"Joicela","ecosystem":[{"indication":"Osteoarthritis","otherDrugs":[{"name":"aceclofenac","slug":"aceclofenac","company":""},{"name":"acetylsalicylic acid","slug":"acetylsalicylic-acid","company":"Endo Pharms"},{"name":"celecoxib","slug":"celecoxib","company":"Gd Searle"},{"name":"choline magnesium trisalicylate","slug":"choline-magnesium-trisalicylate","company":""}],"globalPrevalence":655000000}],"mechanism":{"target":"Prostaglandin G/H synthase 1","targets":[{"gene":"PTGS1","source":"DrugCentral","target":"Prostaglandin G/H synthase 1","protein":"Prostaglandin G/H synthase 1"},{"gene":"PTGS2","source":"DrugCentral","target":"Prostaglandin G/H synthase 2","protein":"Prostaglandin G/H synthase 2"}],"modality":"Small Molecule","drugClass":"lumiracoxib","explanation":"","oneSentence":"","technicalDetail":"Joicela selectively inhibits the cyclooxygenase-2 (COX-2) enzyme, a key component of Prostaglandin G/H synthase 1, thereby reducing the production of prostaglandins and their downstream mediators, such as prostaglandin E2 (PGE2) and thromboxane A2 (TXA2)."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1618","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=LUMIRACOXIB","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LUMIRACOXIB","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:05:06.662113","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:22:15.453732+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"celecoxib","drugSlug":"celecoxib","fdaApproval":"1998-12-31","patentExpiry":"May 27, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"rofecoxib","drugSlug":"rofecoxib","fdaApproval":"1999-05-20","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"valdecoxib","drugSlug":"valdecoxib","fdaApproval":"2001-11-16","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"lumiracoxib","indications":{"approved":[{"name":"Osteoarthritis","source":"DrugCentral","snomedId":396275006,"regulator":"FDA","usPrevalence":null,"globalPrevalence":655000000,"prevalenceMethod":"curated","prevalenceSource":"Arthritis Res Ther, 2023 (PMID:36991481)"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"celecoxib","brandName":"celecoxib","genericName":"celecoxib","approvalYear":"1998","relationship":"same-class"},{"drugId":"rofecoxib","brandName":"rofecoxib","genericName":"rofecoxib","approvalYear":"1999","relationship":"same-class"},{"drugId":"valdecoxib","brandName":"valdecoxib","genericName":"valdecoxib","approvalYear":"2001","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT00348491","phase":"PHASE4","title":"Efficacy of Lumiracoxib in Relieving Moderate to Severe Post-dental Surgery Pain, Compared to Both Placebo and Celecoxib","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-02","conditions":["Pain"],"enrollment":364,"completionDate":""},{"nctId":"NCT00267176","phase":"PHASE4","title":"Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-11","conditions":["Osteoarthritis","Controlled Hypertension"],"enrollment":1020,"completionDate":""},{"nctId":"NCT01481610","phase":"PHASE2","title":"Safety Study of Renal Function in Patients With Chronic Kidney Failure Taking Lumiracoxib or Diclofenac for Arthralgia","status":"TERMINATED","sponsor":"Hospital Central Sur de Pemex","startDate":"2012-01","conditions":["Kidney Failure, Chronic","Arthralgia"],"enrollment":28,"completionDate":"2012-11"},{"nctId":"NCT00145301","phase":"PHASE3","title":"52 Week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability & Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid & Celecoxib 200 mg od in Pts With Primary OA of Hip, Knee, Hand or Spine","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-09","conditions":["Osteoarthritis"],"enrollment":3036,"completionDate":""},{"nctId":"NCT00475800","phase":"PHASE3","title":"Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis(OA)","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-01","conditions":["Osteoarthritis"],"enrollment":833,"completionDate":""},{"nctId":"NCT00476034","phase":"PHASE3","title":"Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-12","conditions":["Osteoarthritis"],"enrollment":1312,"completionDate":""},{"nctId":"NCT00154219","phase":"PHASE3","title":"Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip Osteoarthritis","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-11","conditions":["Osteoarthritis, Hip"],"enrollment":1200,"completionDate":""},{"nctId":"NCT00170872","phase":"PHASE3","title":"6 Week Open-label Trial With Lumiracoxib 200mg o.d. in Primary Knee Osteoarthritis or Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-11","conditions":["Osteoarthritis","Rheumatoid Arthritis"],"enrollment":135,"completionDate":""},{"nctId":"NCT00367315","phase":"PHASE3","title":"Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-09","conditions":["Knee Osteoarthritis"],"enrollment":1684,"completionDate":""},{"nctId":"NCT00267215","phase":"PHASE3","title":"Efficacy and Safety of Lumiracoxib","status":"COMPLETED","sponsor":"Novartis","startDate":"2000-11","conditions":["Osteoarthritis"],"enrollment":330,"completionDate":""},{"nctId":"NCT00366938","phase":"PHASE3","title":"Efficacy and Safety of Lumiracoxib in Patients With Knee Osteoarthritis (OA).","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-09","conditions":["Osteoarthritis, Knee"],"enrollment":1464,"completionDate":""},{"nctId":"NCT00637949","phase":"PHASE3","title":"Safety of Lumiracoxib in Patients With Osteoarthritis","status":"COMPLETED","sponsor":"Novartis","startDate":"2000-12","conditions":["Osteoarthritis"],"enrollment":309,"completionDate":"2001-03"},{"nctId":"NCT00350155","phase":"PHASE4","title":"Video Capsule Endoscopy to Investigate the Safety and Tolerability of Lumiracoxib in the Small Bowel","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-05","conditions":["Healthy Volunteers"],"enrollment":150,"completionDate":""},{"nctId":"NCT00333567","phase":"PHASE4","title":"Efficacy and Safety of Lumiracoxib 400 mg in Arthroscopic Knee Surgery","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-08","conditions":["Pain"],"enrollment":110,"completionDate":""},{"nctId":"NCT00419796","phase":"PHASE4","title":"Effects of Lumiracoxib and Ibuprofen on Blood Pressure and Urinary Eicosanoid Excretion in Osteoarthritis Patients With Controlled Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-11","conditions":["Osteoarthritis With Controlled Hypertension"],"enrollment":78,"completionDate":"2007-09"},{"nctId":"NCT00170781","phase":"PHASE4","title":"Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-06","conditions":["Acute Gouty Arthritis"],"enrollment":234,"completionDate":""},{"nctId":"NCT00170898","phase":"PHASE4","title":"Safety and Efficacy of Lumiracoxib Versus Naproxen in Acute Musculoskeletal Pain","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-11","conditions":["Musculoskeletal Pain"],"enrollment":419,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"011158","UNII":"V91T9204HU","CHEBI":"CHEBI:73044","INN_ID":"8151","UMLSCUI":"C1176415","chemblId":"CHEMBL404108","ChEMBL_ID":"CHEMBL404108","KEGG_DRUG":"D03714","DRUGBANK_ID":"DB01283","PDB_CHEM_ID":" LUR","PUBCHEM_CID":"151166","SNOMEDCT_US":"422506000","IUPHAR_LIGAND_ID":"2897","MESH_SUPPLEMENTAL_RECORD_UI":"C473384"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Novartis Pharmaceuticals UK Limited","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"74%"},"publicationCount":244,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"M01AH06","allCodes":["M01AH06"]},"biosimilarFilings":[],"originalDeveloper":"Novartis Pharmaceuticals UK Limited","recentPublications":[{"date":"2025 Sep 22","pmid":"41002919","title":"Lipid Raft Membrane Interactivity Correlating with Cyclooxygenase-2 Selectivity of Non-Steroidal Anti-Inflammatory Drugs.","journal":"Membranes"},{"date":"2025 Aug 26","pmid":"40859326","title":"The STUB1-TPIT axis regulates the secretion of adrenocorticotrophic hormone in cushing disease.","journal":"Journal of translational medicine"},{"date":"2024 Nov 27","pmid":"39770440","title":"Cyclodextrin-Nanosponge-Loaded Cyclo-Oxygenase-2 Inhibitor-Based Topical Gel for Treatment of Psoriatic Arthritis: Formulation Design, Development, and In vitro Evaluations.","journal":"Pharmaceuticals (Basel, Switzerland)"},{"date":"2025 Jan","pmid":"39510245","title":"The role of the cyclooxygenase-2 pathway in tissue ischemia and revascularization following skeletal muscle injury induced by bothropic snake venom.","journal":"Microvascular research"},{"date":"2024 Sep","pmid":"39114538","title":"Renal effects of selective cyclooxygenase-2 inhibitor anti-inflammatory drugs: A systematic review and meta-analysis.","journal":"Exploratory research in clinical and social pharmacy"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"withdrawn","companyName":"Novartis Pharmaceuticals UK Limited","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"2005","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"UK Medicines and Healthcare Products Regulatory Agency (MHRA)","status":"approved","approval_date":"2003-09-12T00:00:00.000Z","mah":"Novartis Pharmaceuticals UK Limited","brand_name_local":null,"application_number":""},{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":"2011-05-27T00:00:00.000Z","mah":"Novartis","brand_name_local":"Joicela","application_number":"EMEA/H/C/002104"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:22:15.453732+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}